What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Guselkumab demonstrated moderate clinical effectiveness in treating active psoriatic arthritis, showing statistically significant benefits compared to placebo across various outcomes, including disease activity and joint symptoms. However, it has not been directly compared with other biological DMARDs, which limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
Guselkumab’s cost-effectiveness estimates fall within the acceptable range for Healthcare resources, particularly for patients who have had two conventional DMARDs and at least one biological DMARD. The committee concluded that the ICERs were favorable, supporting its use in these populations.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that guselkumab leads to moderate improvements in health-related quality of life, as reported by clinical experts and supported by trial data. However, the improvements are not overwhelmingly large, and the evidence is primarily derived from indirect comparisons.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Guselkumab has an acceptable safety profile, with low rates of adverse events reported in clinical trials. The committee noted that the discontinuation rates were low, suggesting good tolerability, although there are concerns about the generalizability of these rates to the Healthcare population.
Was the drug compared against what payers expect? — Comparator Selection
The clinical trials primarily compared guselkumab to placebo, with limited direct comparisons to other biological DMARDs. While indirect comparisons suggest similar effectiveness to other treatments, the lack of head-to-head trials raises concerns about the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations were not fully representative of the Healthcare population, as they included patients from eastern Europe with different treatment pathways. While some subgroup analyses were conducted, the overall applicability of the trial results to the Healthcare is limited.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Guselkumab can be integrated into existing treatment pathways with minor adjustments, as it is a biological DMARD that fits within the current treatment landscape for psoriatic arthritis. The committee noted that clinicians would welcome this additional treatment option.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicates that guselkumab has a manageable budget impact, particularly with the commercial arrangements in place. The committee concluded that the resource implications are justifiable given the expected health benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two pivotal trials, which, despite some limitations regarding generalizability and potential biases, provide a strong foundation for decision-making. The committee acknowledged the need for further evidence but found the existing data acceptable.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the generalizability of trial results to the Healthcare population and the potential biases introduced by trial design. While the committee recognized the unmet need for additional treatments, these uncertainties may impact the overall confidence in the findings.
